An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Boehringer Receives U.S. FDA Breakthrough Therapy Designation and Initiates Two phase III Trials in MASH for Survodutide On October 8, Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for survodutide (BI 456906), a...
Endocrine Society Endorses Right to IVF Act In June 2024, the Endocrine Society endorsed the Right to IVF Act, introduced by Senators Cory Booker (D-NJ), Patty Murray (D-WA), and Tammy Duckworth (D-IL) to protect and expand nationwide access to fertility treatment, including in vitro fertilization (IVF). The Right to IVF Act would help individuals and families...
By John Newell-Price, MD, PhD, President, Endocrine Society I’ve been a proud member of the Endocrine Society for more than two decades. Each year as October comes around, I renew my membership, and I really encourage you to do so too. If you haven’t already done so, now is the perfect time to renew for...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Priority Review Granted for HER2-low or HER2-ultralow Metastatic Breast Cancer Treatment On October 1, AstraZeneca and Daiichi Sankyo announced that its supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the...
Peak Performance: Previewing the Endocrine Society’s AI in Healthcare Virtual Summit
As Artificial Intelligence (AI) finds its way into all aspects of daily life, soon it could be an important component of scientific research, patient care, and the ins and outs of clinical practice. On November 8 and 9, the Endocrine Society will host the AI in Healthcare Virtual Summit that will cover a variety of...
A new virtual conference will explore how artificial intelligence (AI) can help healthcare providers and scientists efficiently analyze vast amounts of data and make more informed decisions, the Endocrine Society announced today. The Society will host its first-ever Artificial Intelligence in Healthcare Virtual Summit Nov. 8-9. The event will explore AI’s potential to revolutionize patient...
Injectable and gel versions of testosterone replacement therapy have long been considered cumbersome by both patients and providers, for a litany of reasons from being difficult to administer to an overwhelming insurance burden. However, research from ENDO 2024 revealed that a new oral therapy could potentially eliminate these barriers and be a safer option. By...